While the weight loss results were impressive across the group, the cost and side effects remain important barriers for ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Eli Lilly plans to turn India into a growth market by addressing its diabetes and obesity challenges with its new treatment, ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

Novo Nordisk will pay as much as $2 billion for a new obesity drug called UBT251. The company now holds the exclusive rights ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Biomea Fusion (BMEA) announced the presentation of preclinical and clinical data from studies assessing icovamenib at the ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

It is being billed by doctors as the best drug in weight management, compared to similar drugs available in the market ...